EU medicines company reverses course on Eli Lilly’s Alzheimer’s drug

The European Medicines Company (EMA) has reversed its stance on Eli Lilly’s Alzheimer’s drug Kisunla, recommending its approval for restricted use simply months after initially rejecting it as a result of security considerations.

In March, the EMA’s drug security committee stated the dangers of the drug outweighed its advantages, citing uncommon however doubtlessly deadly uncomfortable side effects comparable to mind swelling and bleeding.

Nonetheless, the company now says the drug could be authorised for sufferers who both don’t carry the ApoE4 gene or who carry just one copy of it, as this gene makes sufferers extra inclined to mind bleeding.

Therapies for the neurological illness stay expensive and carry vital dangers, providing solely modest scientific profit. However whereas Kisunla has already been authorized within the US, UK, Japan, and China, Europe’s slower response has raised concern amongst affected person teams.

Alzheimer Europe welcomed the transfer, saying that they appreciated “the cautious strategy that the EMA has taken to establish sufferers prone to profit from therapy and to exclude these at best threat of dangerous side-effects,  comparable to individuals with two copies of the ApoE4 gene.” 

“As with all anti-amyloid therapies, considerations round security stay, and ongoing vigilance will likely be important to make sure a beneficial benefit-risk steadiness in real-world use,” Jean Georges, the Govt Director of Alzheimer Europe stated in a press launch.

This isn’t the primary time the EMA has modified its place on an Alzheimer’s drug. In 2024, it initially rejected Leqembi, developed by US agency Biogen and Japan’s Eisai, earlier than later approving it for a extra slender affected person group.

The EMA’s suggestion is pending a last resolution from the European Fee.

(de)